Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Nuvigil Clear all
Completed Phase 2 Interventional Results available

Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits

NCT00487942
View directory record Official record
Conditions
Schizophrenia
Interventions
armodafinil, placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
12
States / cities
Garden Grove, California • National City, California • Paramount, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 22, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT01072630
View directory record Official record
Conditions
Depression
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
46
States / cities
Birmingham, Alabama • Anaheim, California • Cerritos, California + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 22, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder

NCT00078312
View directory record Official record
Conditions
Narcolepsy, Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Shift-Work Sleep Disorder
Interventions
CEP-10953 (Armodafinil)
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
41
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 22, 2026, 6:48 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

The Nuvigil and Provigil Pregnancy Registry

NCT01792583
View directory record Official record
Conditions
Narcolepsy, Obstructive Sleep Apnea, Shift Work Sleep Disorder
Interventions
Modafinil/armodafinil
Drug
Lead sponsor
Cephalon, Inc.
Industry
Eligibility
Female only
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2023
U.S. locations
1
States / cities
West Chester, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 22, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness

NCT00228553
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, Chronic Shift Work Sleep Disorder
Interventions
Armodafinil 100 to 250 mg/day
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 64 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 22, 2026, 6:48 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia

NCT00772005
View directory record Official record
Conditions
Schizophrenia
Interventions
armodafinil, placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
39
States / cities
Little Rock, Arkansas • Anaheim, California • Escondido, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2012 · Synced Oct 22, 2026, 6:48 AM EDT
Terminated Phase 4 Interventional Results available

Evaluation of Modafinil vs Placebo for Treatment of Anesthesia Delayed Emergence in Obstructive Sleep Apnea

NCT02494102
View directory record Official record
Conditions
Obstructive Sleep Apnea, Delayed Emergence From Anesthesia
Interventions
Modafinil, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 22, 2026, 6:48 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia

NCT02151253
View directory record Official record
Conditions
Nocturia, Daytime Sleepiness
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 90 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 22, 2026, 6:48 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

NCT00983437
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Armodafinil
Drug
Lead sponsor
Cephalon, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
61
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 22, 2026, 6:48 AM EDT
Completed Phase 2 Interventional Results available

Combining Armodafinil With Neuro-rehabilitation to Improve Neurological Recovery and Reduce Disability Post-Stroke

NCT01896128
View directory record Official record
Conditions
Stroke, Cerebrovascular Accident, Hemiparesis
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Burke Rehabilitation Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 22, 2026, 6:48 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression

NCT00518986
View directory record Official record
Conditions
Sleep Disorders, Obstructive Sleep Apnea, Major Depressive Disorder, Dysthymic Disorder
Interventions
armodafinil, placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
62
States / cities
Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 22, 2026, 6:48 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sleepiness and Brain Function: The Effect of Armodafinil in Shift Work Sleep Disorder

NCT00688142
View directory record Official record
Conditions
Shift Work Sleep Disorder
Interventions
Not listed
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 31, 2010 · Synced Oct 22, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma

NCT01160380
View directory record Official record
Conditions
Fatigue, Multiple Myeloma
Interventions
armodafinil, Placebo
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Anaheim, California • Newport Beach, California • West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Oct 22, 2026, 6:48 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

NCT00893789
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Armodafinil, Placebo
Drug · Other
Lead sponsor
Cephalon, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
68
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 22, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT01305408
View directory record Official record
Conditions
Depression
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • Sherman Oaks, California • Temecula, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 22, 2026, 6:48 AM EDT
Completed Phase 2 Interventional Results available

Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT00481195
View directory record Official record
Conditions
Bipolar I Depression
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
42
States / cities
Birmingham, Alabama • Escondido, California • Lafayette, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 22, 2026, 6:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Armodafinil on Simulated Driving

NCT02468856
View directory record Official record
Conditions
Healthy Volunteers
Interventions
armodafinil, Placebo (for armodafinil)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 22, 2026, 6:48 AM EDT
Completed Phase 2Phase 3 Interventional

Use of Armodafinil for Fatigue in Sarcoidosis

NCT00555347
View directory record Official record
Conditions
Sarcoidosis, Fatigue, Sleepiness
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 22, 2026, 6:48 AM EDT
Withdrawn Not applicable Interventional

Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies

NCT01256905
View directory record Official record
Conditions
Parkinsons Disease, Lewy Bodies Disease
Interventions
Armodafinil
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
50 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 22, 2026, 6:48 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS)

NCT00981084
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
armodafinil
Drug
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2013 · Synced Oct 22, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients

NCT02478580
View directory record Official record
Conditions
Obesity, Premature Recovery From Anesthesia
Interventions
Nuvigil, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 22, 2026, 6:48 AM EDT
Terminated Not applicable Interventional Results available

Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients

NCT01169753
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Placebo, Armodafinil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 22, 2026, 6:48 AM EDT
Completed Phase 4 Interventional Results available

"Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"

NCT01023672
View directory record Official record
Conditions
Dementia With Lewy Bodies
Interventions
Armodafinil
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 22, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL

NCT00236080
View directory record Official record
Conditions
Chronic Shift Work Sleep Disorder
Interventions
PROVIGIL 200 mg, Armodafinil 250 mg, Armodafinil 200 mg, Armodafinil 150 mg, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 22, 2026, 6:48 AM EDT